Anders Jungbeck proposed as new member of the Board of Enzymatica

Enzymatica strengthens its Board with competency and experience from the pharmaceutical industry. Anders Jungbeck, vice president of the international pharmaceutical company Actavis, has been proposed as new member of the Board of Enzymatica. Anders Jungbeck has the past 29 years been working in both the Swedish and international pharmaceutical industry in companies as Glaxo, Draco, AstraZeneca and Ratiopharm. - We are very pleased to have Anders Jungbeck to candidate for our Board. By having Anders on the Board we get a good gain in terms of experience from the international